Corgenix Medical Corporation (OTC:CONX), a worldwide developer and marketer of diagnostic test kits, will host a conference call on Monday, February 14, 2011, at 4:00 p.m. EST to discuss the Company’s financial and operating performance for its quarter ended December 31, 2010, and the status of the Company’s product development and marketing activities. Shares of Corgenix closed at $0.11 per share on light volume. The company has a market cap of $4.5 million and a 52-week range between $0.07 and $0.19 per share.Corgenix invites all those interested in hearing management’s discussion of the quarter’s results to join the call by dialing:
U.S. attendees: (800) 862-9098
International attendees: +1 785 424 1051
Conference code is: CORGENIX
A question-and-answer session will follow the presentation by Corgenix management.
A replay will be available for 30 days following the call by dialing (800) 283-7928 for U.S. participants and +1 402 220 0866 for international participants.
Corgenix is in the business of developing and manufacturing specialized diagnostic kits for immunology disorders, vascular diseases and bone and joint disorders, including the world’s only non-blood-based test for aspirin effect. Corgenix diagnostic products are commercialized for use in clinical laboratories throughout the world. The company currently sells over 50 diagnostic products through a global distribution network and has significant experience advancing products through the FDA process.
More information is available at www.corgenix.com.
No comments:
Post a Comment